Elevation of Plasma Cell-Free Hemoglobin in Pulmonary Arterial Hypertension

Chest

Volumn 146, Issue 6, 2014, Pages 1478-1485

  Brittain, Evan L ^a   Janz, David R ^a   Austin, Eric D ^a   Bastarache, Julie A ^a   Wheeler, Lisa A ^a   Ware, Lorraine B ^a   Hemnes, Anna R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CELL FREE HEMOGLOBIN; HEMOGLOBIN; NITRIC OXIDE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; BMPR2 PROTEIN, HUMAN;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENDER; HEART INDEX; HEART RIGHT ATRIUM PRESSURE; HEMODYNAMICS; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; LIVER FUNCTION; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; LUNG WEDGE PRESSURE; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; MIDDLE AGED; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; PULMONARY VENOUS HYPERTENSION; RISK ASSESSMENT; AGED; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; KAPLAN MEIER METHOD; METABOLISM; NONPARAMETRIC TEST; PATHOPHYSIOLOGY; PHYSIOLOGY; PLASMA CELL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; VASCULAR RESISTANCE;

ADULT; AGED; BIOMARKERS; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; CASE-CONTROL STUDIES; FEMALE; HEMODYNAMICS; HEMOGLOBINS; HUMANS; HYPERTENSION, PULMONARY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PLASMA CELLS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; VASCULAR RESISTANCE;

EID: 84964698114     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-0809     Document Type: Article

References (37)

1. 1 Billings, FT IV, Ball, SK, Roberts, LJ II, Pretorius, M, Postoperative acute kidney injury is associated with hemoglobinemia and an enhanced oxidative stress response. Free Radic Biol Med 50:11 (2011), 1480–1487.
2. 2 Reeder, BJ, Svistunenko, DA, Cooper, CE, Wilson, MT, The radical and redox chemistry of myoglobin and hemoglobin: from in vitro studies to human pathology. Antioxid Redox Signal 6:6 (2004), 954–966.
3. 3 Reiter, CD, Wang, X, Tanus-Santos, JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 8:12 (2002), 1383–1389.
4. 4 Meyer, C, Heiss, C, Drexhage, C, et al. Hemodialysis-induced release of hemoglobin limits nitric oxide bioavailability and impairs vascular function. J Am Coll Cardiol 55:5 (2010), 454–459.
5. 5 Gladwin, MT, Kim-Shapiro, DB, Storage lesion in banked blood due to hemolysis-dependent disruption of nitric oxide homeostasis. Curr Opin Hematol 16:6 (2009), 515–523.
6. 6 Minneci, PC, Deans, KJ, Zhi, H, et al. Hemolysis-associated endothelial dysfunction mediated by accelerated NO inactivation by decompartmentalized oxyhemoglobin. J Clin Invest 115:12 (2005), 3409–3417.
7. 7 Donadee, C, Raat, NJH, Kanias, T, et al. Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion. Circulation 124:4 (2011), 465–476.
8. 8 Janz, DR, Bastarache, JA, Peterson, JF, et al. Association between cell-free hemoglobin, acetaminophen, and mortality in patients with sepsis: an observational study. Crit Care Med 41:3 (2013), 784–790.
9. 9 Gladwin, MT, Vichinsky, E, Pulmonary complications of sickle cell disease. N Engl J Med 359:21 (2008), 2254–2265.
10. 10 Natanson, C, Kern, SJ, Lurie, P, Banks, SM, Wolfe, SM, Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. JAMA 299:19 (2008), 2304–2312.
11. 11 Baek, JH, D'Agnillo, F, Vallelian, F, et al. Hemoglobin-driven pathophysiology is an in vivo consequence of the red blood cell storage lesion that can be attenuated in guinea pigs by haptoglobin therapy. J Clin Invest 122:4 (2012), 1444–1458.
12. 12 Farber, HW, Loscalzo, J, Pulmonary arterial hypertension. N Engl J Med 351:16 (2004), 1655–1665.
13. 13 Archer, SL, Michelakis, ED, Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N Engl J Med 361:19 (2009), 1864–1871.
14. 14 Ghofrani, H-A, Galiè, N, Grimminger, F, et al. PATENT-1 Study Group. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 369:4 (2013), 330–340.
15. 15 Badesch, DB, Abman, SH, Simonneau, G, Rubin, LJ, McLaughlin, VV, Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 131:6 (2007), 1917–1928.
16. 16 Buehler, PW, Baek, JH, Lisk, C, et al. Free hemoglobin induction of pulmonary vascular disease: evidence for an inflammatory mechanism. Am J Physiol Lung Cell Mol Physiol 303:4 (2012), L312–L326.
17. 17 Bielecki, M, Kowal, K, Lapinska, A, Chyczewski, L, Kowal-Bielecka, O, Increased release of soluble CD163 by the peripheral blood mononuclear cells is associated with worse prognosis in patients with systemic sclerosis. Adv Med Sci 58:1 (2013), 126–133.
18. 18 Tantawy, AAG, Adly, AAM, Ismail, EAR, Soluble CD163 in young sickle cell disease patients and their trait siblings: a biomarker for pulmonary hypertension and vaso-occlusive complications. Blood Coagul Fibrinolysis 23:7 (2012), 640–648.
19. 19 National Institutes of Health Clinical Center. Vanderbilt University. Acetominophen for the reduction of oxidative injury in severe sepsis (ACROSS). NCT01739361. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. http://clinicaltrials.gov/show/NCT01739361, 2012 Updated December 21, 2013.
20. 20 Larkin, EK, Newman, JH, Austin, ED, et al. Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension. Am J Respir Crit Care Med 186:9 (2012), 892–896.
21. 21 Hoeper, MM, Bogaard, HJ, Condliffe, R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 62:suppl 25 (2013), D42–D50.
22. 22 Guazzi, M, Borlaug, BA, Pulmonary hypertension due to left heart disease. Circulation 126:8 (2012), 975–990.
23. 23 Robbins, IM, Hemnes, AR, Pugh, ME, et al. High prevalence of occult pulmonary venous hypertension revealed by fluid challenge in pulmonary hypertension. Circ Heart Fail 7:1 (2014), 116–122.
24. 24 Sitbon, O, Humbert, M, Jaïs, X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111:23 (2005), 3105–3111.
25. 25 Machado, RF, Gladwin, MT, Pulmonary hypertension in hemolytic disorders: pulmonary vascular disease: the global perspective. Chest 137:6_suppl (2010), 30S–38S.
26. 26 Schaer, DJ, Buehler, PW, Cell-free hemoglobin and its scavenger proteins: new disease models leading the way to targeted therapies. Cold Spring Harb Perspect Med, 3(6), 2013.
27. 27 Rhodes, CJ, Wharton, J, Howard, LS, Gibbs, JSR, Wilkins, MR, Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension. Heart 97:13 (2011), 1054–1060.
28. 28 Hampole, CV, Mehrotra, AK, Thenappan, T, Gomberg-Maitland, M, Shah, SJ, Usefulness of red cell distribution width as a prognostic marker in pulmonary hypertension. Am J Cardiol 104:6 (2009), 868–872.
29. 29 Kline, JA, Marchick, MR, Hogg, MM, Reduction in plasma haptoglobin in humans with acute pulmonary embolism causing tricuspid regurgitation. J Thromb Haemost 7:9 (2009), 1597–1599.
30. 30 Zagorski, J, Marchick, MR, Kline, JA, Rapid clearance of circulating haptoglobin from plasma during acute pulmonary embolism in rats results in HMOX1 up-regulation in peripheral blood leukocytes. J Thromb Haemost 8:2 (2010), 389–396.
31. 31 Ruiter, G, Lankhorst, S, Boonstra, A, et al. Iron deficiency is common in idiopathic pulmonary arterial hypertension. Eur Respir J 37:6 (2011), 1386–1391.
32. 32 Rhodes, CJ, Howard, LS, Busbridge, M, et al. Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes, and mechanistic insights. J Am Coll Cardiol 58:3 (2011), 300–309.
33. 33 Soon, E, Treacy, CM, Toshner, MR, et al. Unexplained iron deficiency in idiopathic and heritable pulmonary arterial hypertension. Thorax 66:4 (2011), 326–332.
34. 34 Decker, I, Ghosh, S, Comhair, SA, et al. High levels of zinc-protoporphyrin identify iron metabolic abnormalities in pulmonary arterial hypertension. Clin Transl Sci 4:4 (2011), 253–258.
35. 35 Ashley-Koch, AE, Elliott, L, Kail, ME, et al. Identification of genetic polymorphisms associated with risk for pulmonary hypertension in sickle cell disease. Blood 111:12 (2008), 5721–5726.
36. 36 Janz, DR, Bastarache, JA, Sills, G, et al. Association between haptoglobin, hemopexin and mortality in adults with sepsis. Crit Care, 17(6), 2013, R272.
37. 37 Adamzik, M, Hamburger, T, Petrat, F, Peters, J, de Groot, H, Hartmann, M, Free hemoglobin concentration in severe sepsis: methods of measurement and prediction of outcome. Crit Care, 16(4), 2012, R125.